Barclays lowered the firm’s price target on Xencor (XNCR) to $6 from $22 and keeps an Underweight rating on the shares post the Q1 report. The firm continues to “de-risk” its biotech models.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR: